Abstract:Introduction Furoscix is a 80mg/10mL buffered formulation of furosemide developed for subcutaneous self-administration in the outpatient setting via a wearable, pre-programmed infusor over 5 hours. In the FREEDOM-HF observational study and the AT HOME-HF randomized trial, patients received Furoscix at study entry, transitioned back to oral diuretics when clinically indicated and were followed for 30 days. The objective of this analysis was to describe Furoscix dosing patterns and associated short-term changes in renal function (SCr) and potassium level (K+). Methods Both studies enrolled hemodynamically stable patients with NYHA Class II-IV chronic HF with worsening signs and symptoms of congestion requiring augmented diuresis (FREEDOM-HF in ED before discharge, AT-HOME HF as outpatient). Changes from baseline in SCr and K+ were assessed in both trials at Day 3, and incidence of worsening renal function (WRF) (> 25% increase in SCr) and hypokalemia (mild: K+<3.5 mg/dL; moderate: K+<3.0 mg/dL) were captured. Results were stratified based on number of Furoscix doses administered and baseline daily total oral furosemide equivalent dosage (<120 mg or >120 mg). Results A total of 58 patients were included, 24 from FREEDOM-HF and 34 from AT-HOME. The mean (range) number of per patient doses over the study duration was 6 (2-10) in FREEDOM-HF and 4 (1-9) in AT-HOME. All patients received at least one Furoscix dose within 3 days of enrollment; 11 received 1 dose and 47 two or more doses. 83% of total Furoscix doses administered in the 30-day study period were administered within the first 7 days, and 61% were administered within the first 3 days. Twice daily dosing was utilized < 5% of study days. At baseline, 38% of patients had Stage 2 CKD (n=22) followed by Stages 3A and 3B (n=13, 24% for each). Mean increase in SCr was 0.11±0.2 mg/dL; 5 (9%) patients experienced WRF (2 patients after 1 dose, 2 patients after 3 doses and 1 patient after 4 doses). All cases of WRF resolved spontaneously and/or with transient holding of diuretics. Overall, serum K+ increased by a mean of 0.01±0.6 mg/dL. 5 patients (9%) developed hypokalemia during the first 3 days; 4 mild and 1 moderate. 35 patients (60%) received K+ with their Furoscix dosing. Neither the number of Furoscix doses nor baseline furosemide equivalent dose had a statistically significant impact on change in SCr or K+. Conclusions Across both studies, over 80% of Furoscix doses were administered within the first 7 days and over 60% were administered within the first 3 days. At day 3 (first clinic visit in both trials), the incidence of hypokalemia and worsening renal function was <10% and was not related to number of Furoscix doses given or baseline renal function.

Subcutaneous Furosemide: A Novel to Euvolemia

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion

Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure

The Role of Subcutaneous Furosemide in Heart Failure Management: A Systematic Review

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF)

Early continuous ultrafiltration in Chinese patients with congestive heart failure (EUC-CHF): study protocol for an open-label registry-based prospective clinical trial.

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial

Analysis Of Subcutaneous Furosemide Dosing Patterns And Impact On SCr And K+ In The Freedom-HF And AT HOME Studies

Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intra-patient Comparison of Three Diuretic Regimens (DEA-HF)

Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation

The acute effects of furosemide in acute heart failure assessed by remote dielectric sensing. A protocol

Treatment of Acute Decompensated Chronic Heart Failure: Furosemide vs Furosemide and Metolazone: A Cross-Sectional Comparative Study

Comparison of three diuretic treatment strategies for patients with acute decompensated heart failure

The furosemide stress test: current use and future potential

Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction

Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs

Simultaneous Use of Hypertonic Saline and IV Furosemide for Fluid Overload: A Systematic Review and Meta-Analysis

Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure

Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome

Neurohormonal Effects of Intravenous Dopamine in Patients with Acute Heart Failure

Combination of diuretics to overcome diuretic resistance in acute heart failure: systematic review and updated network meta-analysis